AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.
AAVantgarde Bio has raised $141.0M in total funding. The most recent round was Series B. The last funding was announced in November 2025.
AAVantgarde Bio's investors include CDP Venture Capital, Schroders Capital, Sofinnova Partners, Forbion Capital Partners, Longwood Fund.
AAVantgarde Bio is headquartered in Milano, Italy.
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.
AAVantgarde Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AAVantgarde Bio — Funding & Investors." VCBacked, November 3, 2025, https://www.vcbacked.co/company/aavantgarde-bio. Accessed July 19, 2026.
VCBacked. (2025). AAVantgarde Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/aavantgarde-bio
{{cite web |title=AAVantgarde Bio — Funding & Investors |url=https://www.vcbacked.co/company/aavantgarde-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated